FR1525186A
(fr)
|
1967-03-29 |
1968-05-17 |
Roussel Uclaf |
Nouvelles pénicillines et procédé de préparation
|
EP0028489B1
(en)
|
1979-11-05 |
1983-10-05 |
Beecham Group Plc |
Enzyme derivatives, and their preparation
|
DE4034829A1
(de)
|
1990-11-02 |
1992-05-07 |
Merck Patent Gmbh |
Cyclopeptide
|
JP3190431B2
(ja)
|
1991-07-01 |
2001-07-23 |
三菱化学株式会社 |
ケトン誘導体
|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
WO1996034010A2
(en)
|
1995-03-29 |
1996-10-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5624936A
(en)
|
1995-03-29 |
1997-04-29 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU717298B2
(en)
|
1996-04-03 |
2000-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
PE121699A1
(es)
|
1997-02-18 |
1999-12-08 |
Boehringer Ingelheim Pharma |
Heterociclos biciclicos disustituidos como inhibidores de la trombina
|
ZA985247B
(en)
|
1997-06-19 |
1999-12-17 |
Du Pont Merck Pharma |
Guanidine mimics as factor Xa inhibitors.
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
KR100898094B1
(ko)
|
1998-03-19 |
2009-05-18 |
버텍스 파마슈티칼스 인코포레이티드 |
카스파제의 억제제
|
ES2310039T3
(es)
|
1998-05-26 |
2008-12-16 |
Warner-Lambert Company Llc |
Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
|
US6307049B1
(en)
|
1998-09-30 |
2001-10-23 |
The Procter & Gamble Co. |
Heterocyclic 2-substituted ketoamides
|
ID29979A
(id)
|
1999-01-02 |
2001-10-25 |
Aventis Pharma Gmbh |
Turunan asam malonat baru, proses pembuatannya, penggunaannya dan komposisi sediaan farmasi yang mengandung bahan tersebut (penghambatan aktivitas faktor xa)
|
EP1016663A1
(en)
|
1999-01-02 |
2000-07-05 |
Aventis Pharma Deutschland GmbH |
Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
|
ATE281466T1
(de)
|
1999-04-09 |
2004-11-15 |
Abbott Gmbh & Co Kg |
Niedermolekulare inhibitoren von komplementproteasen
|
CA2383008A1
(en)
|
1999-06-14 |
2000-12-21 |
Amanda Jane Lyons |
Compounds
|
DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
EP1125925A1
(en)
|
2000-02-15 |
2001-08-22 |
Applied Research Systems ARS Holding N.V. |
Amine derivatives for the treatment of apoptosis
|
MXPA02010452A
(es)
|
2000-05-11 |
2003-06-06 |
Bristol Myers Squibb Co |
Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento.
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
AR035216A1
(es)
|
2000-12-01 |
2004-05-05 |
Astrazeneca Ab |
Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
|
WO2003011222A2
(en)
|
2001-07-27 |
2003-02-13 |
Merck & Co., Inc. |
Thrombin inhibitors
|
US6951840B2
(en)
|
2001-08-31 |
2005-10-04 |
Eli Lilly And Company |
Lipoglycopeptide antibiotics
|
DE60233335D1
(de)
|
2001-09-21 |
2009-09-24 |
Bristol Myers Squibb Co |
Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
|
US6649606B1
(en)
|
2001-11-09 |
2003-11-18 |
Bristol-Myers Squibb Co. |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
AU2002316317A1
(en)
|
2002-06-18 |
2003-12-31 |
The Scripps Research Institute |
Synthesis of diazonamide "a" core
|
US20040180855A1
(en)
|
2003-02-19 |
2004-09-16 |
Schumacher William A. |
Methods of treating thrombosis with reduced risk of increased bleeding times
|
US7138412B2
(en)
|
2003-03-11 |
2006-11-21 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives useful as serine protease inhibitors
|
US7129264B2
(en)
|
2003-04-16 |
2006-10-31 |
Bristol-Myers Squibb Company |
Biarylmethyl indolines and indoles as antithromboembolic agents
|
CA2531796A1
(en)
|
2003-08-08 |
2005-02-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions, and methods of use
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
US7429604B2
(en)
|
2004-06-15 |
2008-09-30 |
Bristol Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
MX2007000490A
(es)
|
2004-07-12 |
2007-06-11 |
Idun Pharmaceuticals Inc |
Analogos de tetrapeptido.
|
US7459564B2
(en)
|
2005-01-13 |
2008-12-02 |
Bristol-Myers Squibb Company |
Substituted biaryl compounds as factor XIa inhibitors
|
US20060183771A1
(en)
|
2005-02-17 |
2006-08-17 |
Seiffert Dietmar A |
Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
|
WO2007047608A2
(en)
|
2005-10-14 |
2007-04-26 |
Epix Pharmaceuticals, Inc. |
Fibrin targeted therapeutics
|
WO2007054453A2
(en)
|
2005-11-11 |
2007-05-18 |
F. Hoffmann-La Roche Ag |
Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
|
WO2007070818A1
(en)
|
2005-12-14 |
2007-06-21 |
Bristol-Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
WO2007070826A1
(en)
|
2005-12-14 |
2007-06-21 |
Bristol-Myers Squibb Company |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
|
WO2007070816A2
(en)
|
2005-12-14 |
2007-06-21 |
Bristol-Myers Squibb Company |
Thiophene derivatives as factor xia inhibitors
|
AR058380A1
(es)
|
2005-12-23 |
2008-01-30 |
Bristol Myers Squibb Co |
Inhibidores del factor viia macrociclicos utiles como anticoagulantes
|
WO2008076805A2
(en)
|
2006-12-15 |
2008-06-26 |
Bristol-Myers Squibb Company |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
|
PE20081775A1
(es)
|
2006-12-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
TW200848024A
(en)
|
2007-06-13 |
2008-12-16 |
Bristol Myers Squibb Co |
Dipeptide analogs as coagulation factor inhibitors
|
US8324199B2
(en)
|
2008-03-13 |
2012-12-04 |
Bristol-Myers Squibb Company |
Pyridazine derivatives as factor xia inhibitors
|
US8624040B2
(en)
|
2009-06-22 |
2014-01-07 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2011002520A2
(en)
|
2009-07-02 |
2011-01-06 |
Angion Biomedica Corp. |
Small molecule inhibitors of parp activity
|
WO2011017296A1
(en)
|
2009-08-04 |
2011-02-10 |
Schering Corporation |
4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
|
PE20160841A1
(es)
*
|
2010-02-11 |
2016-09-10 |
Bristol Myers Squibb Co |
Macrociclos como inhibidores del factor de coagulacion (fxia)
|
EP2729150B1
(en)
|
2011-07-08 |
2016-09-14 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
TW201319068A
(zh)
*
|
2011-08-05 |
2013-05-16 |
必治妥美雅史谷比公司 |
作為xia因子抑制劑之環狀p1接合劑
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
JP6033318B2
(ja)
|
2011-10-14 |
2016-11-30 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物
|
ES2572908T3
(es)
|
2011-10-14 |
2016-06-03 |
Bristol-Myers Squibb Company |
Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
|
EP3309148A1
(en)
|
2011-10-14 |
2018-04-18 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
GB2497806A
(en)
|
2011-12-21 |
2013-06-26 |
Ono Pharmaceutical Co |
Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
|
DK2794597T3
(en)
|
2011-12-21 |
2018-01-15 |
Ono Pharmaceutical Co |
PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
|
US20140350034A1
(en)
|
2012-01-27 |
2014-11-27 |
Novartis Ag |
Aminopyridine derivatives as plasma kallikrein inhibitors
|
EP2807157A1
(en)
|
2012-01-27 |
2014-12-03 |
Novartis AG |
5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
|
JP2015083542A
(ja)
|
2012-02-08 |
2015-04-30 |
大日本住友製薬株式会社 |
3位置換プロリン誘導体
|
JP6348900B2
(ja)
|
2012-05-10 |
2018-06-27 |
バイエル ファーマ アクチエンゲゼルシャフト |
凝固因子xiおよび/またはその活性化形態である因子xiaに結合しうる抗体ならびにその用途
|
GB201209138D0
(en)
|
2012-05-24 |
2012-07-04 |
Ono Pharmaceutical Co |
Compounds
|
WO2014014050A1
(ja)
|
2012-07-19 |
2014-01-23 |
大日本住友製薬株式会社 |
1-(シクロアルキルカルボニル)プロリン誘導体
|
CA2880866A1
(en)
*
|
2012-08-03 |
2014-02-06 |
Bristol-Myers Squibb Company |
Dihydropyridone p1 as factor xia inhibitors
|
US20140038969A1
(en)
*
|
2012-08-03 |
2014-02-06 |
Bristol-Myers Squibb Company |
Dihydropyridone p1 as factor xia inhibitors
|
WO2014059202A1
(en)
|
2012-10-12 |
2014-04-17 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
EP2906551B1
(en)
|
2012-10-12 |
2018-02-28 |
Bristol-Myers Squibb Company |
Crystalline forms of a factor xia inhibitor
|
EP2906541B1
(en)
|
2012-10-12 |
2017-11-22 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
WO2014120346A1
(en)
|
2012-12-19 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
GB201300304D0
(en)
|
2013-01-08 |
2013-02-20 |
Kalvista Pharmaceuticals Ltd |
Benzylamine derivatives
|
GB2510407A
(en)
|
2013-02-04 |
2014-08-06 |
Kalvista Pharmaceuticals Ltd |
Aqueous suspensions of kallikrein inhibitors for parenteral administration
|
EP2978751B1
(en)
|
2013-03-25 |
2018-12-05 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
|
TWI633089B
(zh)
|
2013-03-28 |
2018-08-21 |
拜耳製藥股份有限公司 |
經取代的酮基吡啶衍生物
|
ES2633248T3
(es)
|
2013-07-23 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Derivados de oxopiridina sustituidos y su uso como factor XIa e inhibidores de calicreína plasmática
|
WO2015044165A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
US20160244437A1
(en)
|
2013-09-26 |
2016-08-25 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
WO2015044169A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
US20160280699A1
(en)
|
2013-09-26 |
2016-09-29 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
US20160237045A1
(en)
|
2013-09-26 |
2016-08-18 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
EP3049390A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
EP3049406A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
|
AR097755A1
(es)
|
2013-09-26 |
2016-04-13 |
Bayer Pharma AG |
Derivados sustituidos de fenilalanina como moduladores del factor xia
|
EP3049435A4
(en)
|
2013-09-27 |
2017-03-29 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
WO2015054087A1
(en)
|
2013-10-07 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
FACTOR XIa INHIBITORS
|
JP6337750B2
(ja)
|
2013-11-22 |
2018-06-06 |
小野薬品工業株式会社 |
化合物
|
EP3095786A4
(en)
|
2014-01-14 |
2017-10-11 |
Sumitomo Dainippon Pharma Co., Ltd. |
Condensed 5-oxazolidinone derivative
|
NO2760821T3
(lt)
|
2014-01-31 |
2018-03-10 |
|
|
LT3099687T
(lt)
|
2014-01-31 |
2018-09-10 |
Bristol-Myers Squibb Company |
Makrociklai su heterociklinėmis p2' grupėmis kaip faktoriaus xia inhibitoriai
|
FI3102200T3
(fi)
|
2014-02-07 |
2023-05-31 |
Exithera Pharmaceuticals Inc |
Terapeuttisia yhdisteitä ja koostumuksia
|
EP3104701B1
(en)
|
2014-02-11 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
WO2015123093A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
US9676723B2
(en)
|
2014-02-11 |
2017-06-13 |
Merck Sharp & Dohme Corp |
Factor XIa inhibitors
|
WO2015120777A1
(zh)
|
2014-02-14 |
2015-08-20 |
四川海思科制药有限公司 |
一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
|
NZ724250A
(en)
|
2014-03-07 |
2022-02-25 |
Biocryst Pharm Inc |
Human plasma kallikrein inhibitors
|
US9969724B2
(en)
|
2014-04-16 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Factor IXa inhibitors
|
US9808445B2
(en)
|
2014-04-16 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Factor IXa inhibitors
|
KR20150136294A
(ko)
|
2014-05-27 |
2015-12-07 |
주식회사 레고켐 바이오사이언스 |
인자 XIa 억제 활성을 가지는 신규한 화합물
|
MX2016015484A
(es)
|
2014-05-28 |
2017-03-23 |
Merck Sharp & Dohme |
Inhibidores del factor xia.
|
WO2016046157A1
(de)
|
2014-09-24 |
2016-03-31 |
Bayer Pharma Aktiengesellschaft |
Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
|
NO2721243T3
(lt)
|
2014-10-01 |
2018-10-20 |
|
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
WO2016093285A1
(ja)
|
2014-12-10 |
2016-06-16 |
小野薬品工業株式会社 |
ジヒドロインドリジノン誘導体
|
EP3310777B1
(en)
|
2015-06-19 |
2019-10-09 |
Bristol-Myers Squibb Company |
Diamide macrocycles as factor xia inhibitors
|